Drug Discovery World

MAY 15, 2024

Dr Catherine Beech , CEO at Exonate and Dr Pete Adamson , CSO at Breye Therapeutics discuss the need for better therapies to treat diabetic retinal disease and current progress in the field. Specific numerical values (steps) denote the severity of NPDR, with 47-53 describing the moderately severe disease. orally administered compounds.

Disease 162

Disease Treatment Therapies Pharmaceuticals 162

Agency IQ

FEBRUARY 2, 2024

Diagnostics landscape analysis: Key issues and a look ahead at 2024 Diagnostic regulation in the U.S. Following significant policy proposals in recent years, 2024 is gearing up to be a profoundly impactful year for diagnostics developers and the policymakers who regulate them. is a constantly evolving topic. In the U.S., In the E.U.,

FDA 40

FDA Regulations Laboratories Production 40

Drug Discovery World

JULY 26, 2024

While the shadow of the pandemic recedes, its effects linger in the form of a market correction and an evolving healthcare landscape. One area where the candidates disagree sharply is market competition. Conversely, Trump champions free market competition and biosimilars.

Science 130

Science Government Biosimilars Marketing 130